Clinical trials: Stage IV Lymphoma
Cachexia, Lymphoma
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
RATIONALE: Celecoxib may help relieve moderate or severe pain associated with cancer. It may also decrease weight loss and improve muscle strength in cancer patients.
- Conditions
- Cachexia, Lymphoma, Melanoma (Skin), Ovarian Cancer
- Trial name
- NCT00093678
- Testing
- celecoxib, anticachectic therapy, nutritional support
- Sponsor
- Eastern Cooperative Oncology Group
Graft Versus Host Disease, Leukemia
Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and melphalan, before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Myeloma
- Trial name
- ProT4 (NCT01240525)
- Testing
- CD4 DLI, No DLI
- Where
- 11 sites in United Kingdom
- Volunteers
- 114 people
- Sponsor
- University College, London
Leukemia, Lymphoma
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00002718
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Leukemia, Lymphoma
Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00324779
- Testing
- rituximab
- Where
- 38 sites in Germany, Switzerland
- Volunteers
- 79 people
- Sponsor
- University Hospital Erlangen
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of dasatinib in treating patients with solid tumors or lymphomas that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia, Adult Hepatocellular Carcinoma, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
- Trial name
- NCT00608361
- Testing
- Dasatinib, Pharmacological Study
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)
RATIONALE: Mycophenolate mofetil added to immunosuppressive treatment regimens may be effective in treating newly diagnosed chronic graft-versus-host disease caused by stem cell transplantation.
- Trial name
- NCT00089141
- Testing
- mycophenolate mofetil
- Where
- 16 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Martin, Paul
Lymphoma
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00004031
- Testing
- rituximab, CHOP regimen, carmustine
- Where
- 15 sites in United States, Canada
- Volunteers
- 397 people
- Sponsor
- SWOG Cancer Research Network
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases
RATIONALE: Studying a diagnostic biomarker test in blood samples from patients who have undergone a donor stem cell transplant for cancer may help doctors plan treatment.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia
- Trial name
- NCT00813501
- Testing
- immunosuppressive therapy, immunological diagnostic method, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
Lymphoma, Large B-Cell, Diffuse
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
This multicenter, randomized, open label parallel-group study will evaluate the efficacy and safety of subcutaneous versus intravenous MabThera/Rituxan (rituximab) in combination with CHOP chemotherapy in patients with previously…
- Trial name
- NCT01649856
- Testing
- CHOP, rituximab [MabThera/Rituxan]
- Where
- 186 sites in Algeria, Argentina and 25 more
- Volunteers
- 572 people
- Sponsor
- Hoffmann-La Roche
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma
Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients
The goal of this clinical trial is to study the feasibility and efficacy of anti-CD22:TCRz:4-1BB chimeric antigen receptor (CAR)-modified T (CAR-T) cells in treating recurrent patients with refractory or resistant lymphoma to…
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Stage III/IV Adult Diffuse Large Cell Lymphoma
- Trial name
- MendCART (NCT02721407)
- Testing
- Retroviral vector-transduced autologous T cells to express CD22-specific CARs
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xinqiao Hospital of Chongqing
Central Nervous System Lymphoma
Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL)
The aim of the study is to deliver primary systemic high-dose methotrexate (MTX) treatment to PCNSL patients and to define the role of whole brain irradiation (WBI) in primary therapy, i.e., to analyze whether patients who have…
- Trial name
- NCT00153530
- Testing
- methotrexate, radiotherapy
- Where
- Germany
- Volunteers
- 604 people
- Sponsor
- Charite University, Berlin, Germany
Chronic Myeloproliferative Disorders, Leukemia
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- Bu Flu TBI (NCT00245037)
- Testing
- therapeutic allogeneic lymphocytes, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- OHSU Knight Cancer Institute
Lymphoma, B-cell, Diffuse
Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma
For SyB L-0501RI administered by an intravenous rapid infusion in combination with rituximab, the safety will be investigated in previously untreated patients with low-grade B-cell non-Hodgkin's lymphoma (Lg-B-NHL) or mantle cell…
- Trial name
- NCT03900377
- Testing
- SyB L-0501RI
- Where
- 14 sites in Japan
- Volunteers
- 37 people
- Sponsor
- SymBio Pharmaceuticals
Lymphoma
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
RATIONALE: To evaluate the efficacy of a new high intensity chemotherapy regimen with thalidomide maintenance in patients with newly diagnosed mantle cell lymphoma PURPOSE: This phase II trial is studying how well giving…
- Trial name
- NCT00450801
- Testing
- Rituximab, Cyclophosphamide, Cytarabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Miami
Lymphoma
Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous peripheral stem cell transplantation may allow the…
- Trial name
- CBV (NCT00005613)
- Testing
- cyclophosphamide, etoposide, BCNU
- Where
- 2 sites in United States
- Volunteers
- 147 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer, Leukemia
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00003425
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Kentucky
Lymphoma
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- ESHAP (NCT00732498)
- Testing
- Methylprednisolone, Etoposide, Cytarabine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Arizona
Leukemia, Lymphoma
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00176475
- Testing
- rituximab, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Medicine and Dentistry of New Jersey